Roivant Health

Roivant Sciences is a commercial-stage biopharmaceutical company that operates through a unique "Vant" model, creating nimble, focused subsidiaries to develop and commercialize medicines and healthcare technologies. Founded in 2014, the company focuses on therapeutic areas including immunology, inflammation, and rare diseases, with a pipeline featuring late-stage candidates like brepocitinib and IMVT-1402. Roivant also operates "Roivant Health," a business unit dedicated to launching health technology companies such as Datavant and VantAI to improve drug development and delivery. The company has achieved multiple FDA approvals and successfully executed major strategic transactions, including the sale of Telavant to Roche and Dermavant to Organon. Roivant's decentralized approach allows for efficient capital allocation and rapid advancement of diverse therapeutic programs.